Argenx's FB102 Meets Primary Endpoint In Phase 2 Celiac Disease Study Versus Placebo With No New Safety Signals; Company Will Advance First-In-Class CD122 Inhibitor Into Phase 3 Development

Benzinga

2026.10.08 05:40 (GMT+0)

Benzinga에서 열기